Viscosupplementation Market Report Scope & Overview:

The Viscosupplementation Market was valued at USD 5.22 Billion in 2025 and is expected to reach USD 11.43 Billion by 2035, growing at a CAGR of 8.15% from 2026-2035.

The Viscosupplementation Market growth is mainly driven by the increasing incidences of osteoarthritis, which is a condition involving the gradual degeneration of articular cartilage, synovium inflammation, and remodeling of subchondral bone causing pain, stiffness, and decreased mobility of joints. Viscosupplementation is a treatment approach entailing the administration of hyaluronic acid, which is present in the synovial fluid of joints and acts to alleviate pain, increase mobility, and restore lubrication. It has gained widespread popularity in the recent years owing to the fact that it can serve as an effective minimally-invasive solution to joint diseases without surgery.

The growing incidence of osteoarthritis caused by factors such as sedentary lifestyle, aging population, and obesity trends will continue to drive the demand for viscosupplements. Improved manufacturing techniques for hyaluronic acid and changing guidelines advocating one-shot treatments are expected to continue driving market growth over the coming years.

In January 2024, Zimmer Biomet launched VISCO3, a three-injection high-molecular-weight hyaluronate treatment for moderate-stage knee osteoarthritis, across several international markets. Clinical trial data revealed a positive safety profile, a 52% reduction in pain at 12 weeks, and prolonged symptom alleviation lasting up to six months, reflecting continued industry investment in evidence-backed multi-injection viscosupplementation therapies.

Viscosupplementation Market Trends

• Growing clinical guideline support for single-injection protocols improving patient compliance.

• Rising adoption of cross-linked hyaluronic acid formulations offering longer-lasting pain relief.

• Continued expansion of viscosupplementation applications beyond knee to hip and shoulder joints.

• Increasing manufacturer investment in bacterial fermentation-derived, non-avian hyaluronic acid production.

• Expanding portfolio optimization through strategic divestitures focused on core HA-based therapies.

U.S. Viscosupplementation Market Outlook

The U.S. Viscosupplementation Market was valued at USD 1.92 Billion in 2025 and is expected to reach USD 5.18 Billion by 2035, growing at a CAGR of 10.44% from 2026-2035.

U.S. Viscosupplementation Market growth is expected to get further impetus owing to the rising numbers of patients diagnosed with osteoarthritis, rising demand for alternative treatments not involving surgery, and the presence of a high number of key players developing hyaluronic acid-based treatments in the country. Rising developments in hyaluronic acid treatments through consistent innovations made by the players to develop newer generation regenerative treatments would support domestic market growth. Future advancements in regulatory pipeline of innovative single-injection and cartilage regeneration treatments would further support the growth of the domestic market.

Anika Therapeutics continues to advance its regulatory pipeline for next-generation hyaluronic acid-based products, having filed the second module of its Hyalofast premarket approval application with the FDA and remaining engaged with the agency to define the regulatory pathway for Cingal, its novel single-injection osteoarthritis pain management product combining proprietary cross-linked hyaluronic acid with a fast-acting steroid. Each product represents an incremental U.S. addressable market opportunity of at least USD 1 billion, reflecting continued domestic investment in expanding the clinical and commercial reach of hyaluronic acid-based joint therapies.

Viscosupplementation Market Segment Analysis

• By Dosage, the Three Injections segment dominated the Viscosupplementation Market with approximately 48.90% share in 2025, while the Single Injection segment is the fastest growing with a CAGR of approximately 8.90%.

• By Application Site, the Knee segment dominated the Viscosupplementation Market with approximately 73.88% share in 2025, while the Shoulders segment is the fastest growing with a CAGR of approximately 9.02%.

• By Source, the Avian-Derived segment dominated the Viscosupplementation Market with approximately 58.50% share in 2025, while the Non-Avian segment is the fastest growing with a CAGR of approximately 9.20%.

• By End-User, the Hospitals segment dominated the Viscosupplementation Market with approximately 41.74% share in 2025, while the Ambulatory Surgical Centers segment is the fastest growing with a CAGR of approximately 9.69%.

By Dosage, Three Injections dominates and Single Injection grows fastest

The Three Injections dosage category continues to dominate the Viscosupplementation Market due to its proven efficacy in providing symptomatic relief to the sufferers of osteoarthritis through the improvement in the functioning of joints. The popularity of the dosage segment stems from its clinical acceptability as the standard protocol along with optimal treatment duration, dose, and administration along with being widely accepted among medical practitioners dealing with moderate to severe knee osteoarthritis patients.

Single injection dosage category is anticipated to grow at the fastest pace during the forecast period due to its ease of administration, fewer visits to clinics, and better compliance compared to multi-dose treatment. Single injections dosage category is mainly characterized by innovations in the cross-linked hyaluronic acid dosage category.

By Application Site, Knee dominates and Others grows fastest

Knee applications remain the dominant application site segment within the Viscosupplementation Market, reflecting the joint's high susceptibility to osteoarthritis and the extensive clinical evidence supporting viscosupplementation as an effective knee osteoarthritis treatment. This segment benefits from decades of accumulated clinical data and established treatment protocols that continue to support broad adoption across knee osteoarthritis patient populations.

Shoulder joints, are emerging as the fastest-growing application site segment, driven by orthopedic surgeons increasingly recognizing viscosupplementation efficacy for symptomatic hip and shoulder osteoarthritis. This segment focuses on ultrasound-guided or fluoroscopy-directed intra-articular injection techniques enabling reliable therapeutic delivery to deeper joint anatomy, positioning these emerging application sites to capture growing demand as clinical evidence for non-knee applications continues to expand.

By Source, Avian-Derived dominates and Non-Avian grows fastest

The Avian-Derived hyaluronic acid accounts for the major source segment in the Viscosupplementation Market on account of the well-known and longstanding process of production involving rooster combs and enabling the development of various commercial viscosupplementation drugs. The segment capitalizes on years of established manufacturing processes and vast experience which continue to drive its inclusion into many popular drugs.

The Non-Avian (fermentation from bacteria) hyaluronic acid is fast catching up as the fastest growing source segment owing to the advances in the manufacturing process which facilitate the manufacture of high-quality hyaluronic acid without using any animal-based raw material. The source segment is primarily focused on minimizing the risks of allergies and dependence on the supply chain of avian-derived material.

By End-User, Hospitals dominates and Ambulatory Surgical Centers grows fastest

Hospitals remain the dominant end-user segment within the Viscosupplementation Market, reflecting their established infrastructure for administering intra-articular injections and their role as the primary site of care for complex osteoarthritis management. This segment benefits from comprehensive diagnostic and treatment capabilities that continue to support hospital-based viscosupplementation administration across diverse patient populations.

Ambulatory Surgical Centers are emerging as the fastest-growing end-user segment, driven by the efficient delivery of minimally invasive products in key sites of care that offer patients faster, more cost-effective treatment access relative to hospital settings. This segment focuses on streamlined outpatient administration suited to routine viscosupplementation procedures, positioning ambulatory surgical centers to capture growing demand as the broader healthcare system continues shifting toward lower-cost, outpatient-based care delivery models.

Regional Analysis

North America Viscosupplementation Market Insights

North America held approximately 41.60% of the global Viscosupplementation Market in 2025 owing to the increase in cases of osteoarthritis patients in the region and presence of leading companies developing hyaluronic acid-based treatment therapies. The U.S. is the key player influencing regional demand dynamics on account of a large pool of patients, robust reimbursement environment, and high adoption rate of viscosupplementation therapy.

Canada adds up to the regional demand through North America's healthcare and orthopedic treatment system. Advancements in regulatory pipeline of next-generation hyaluronic acid-based treatment products in the country further accentuate the dominance of the region as the largest regional market of viscosupplementation.

Asia Pacific Viscosupplementation Market Insights

Asia Pacific is projected to expand at the fastest CAGR of around 9.60% across the Viscosupplementation Market during the 2026-2035 forecast period, driven by a growing aging population, rising prevalence of knee osteoarthritis, and increasing awareness of non-surgical treatment options. China represents the largest single contributor within the region, supported by aging demographics, improving healthcare infrastructure, and government initiatives promoting non-surgical osteoarthritis management.

Japan and South Korea contribute additional regional demand, supported by established healthcare systems and rising adoption of advanced orthopedic treatments. Continued economic growth and expanding healthcare access across the broader region further reinforce Asia Pacific's position as the fastest-growing global market for viscosupplementation.

Europe Viscosupplementation Market Insights

Europe presents a considerable regional market for viscosupplementation treatments with regards to the healthcare infrastructure in Germany, development of orthopedic treatment facilities, and growing need for minimally invasive therapies for osteoarthritis. Germany is considered to be a considerable market for viscosupplementation thanks to its well-developed healthcare system, orthopedic facilities, and companies that work on the development of therapies based on hyaluronic acid. Prevalence of osteoarthritis in older patients, growing awareness of physicians and the use of non-invasive methods of therapy are the factors that are going to promote the growth of viscosupplementation utilization.

France and the United Kingdom present an additional considerable demand for viscosupplementation in Europe owing to the developed healthcare systems, availability of orthopedic treatment facilities, and growing demand for minimally invasive therapies for osteoarthritis. With aging populations and increasing prevalence of knee and other types of joint problems, there is an increase in consideration of non-invasive treatment options by healthcare facilities. Clinical research, physician awareness and changing protocols are going to support the use of hyaluronic acid injections.

MEA & Latin America Viscosupplementation Market Insights

The Middle East & Africa region remains a smaller contributor to global viscosupplementation demand, with growth concentrated in Gulf markets such as the United Arab Emirates and Saudi Arabia, where improving healthcare infrastructure and expanding orthopedic services are increasing treatment access. Rising osteoarthritis prevalence, aging populations, and growing awareness of minimally invasive joint treatments are supporting adoption of hyaluronic acid injections. South Africa represents an important African market, supported by comparatively developed healthcare infrastructure, expanding private healthcare services, and increasing availability of advanced orthopedic therapies.

Latin America’s viscosupplementation market is led by Brazil, supported by its expanding healthcare infrastructure, established orthopedic care network, and increasing awareness of osteoarthritis management. The country’s substantial burden of knee osteoarthritis is creating greater demand for non-surgical joint pain treatments, while improving healthcare access is supporting broader treatment availability. Argentina and other regional markets contribute additional demand as outpatient orthopedic services develop. Increasing physician awareness, product availability, and gradual improvements in healthcare infrastructure are expected to support steady viscosupplementation market development across Latin America.

Market Dynamics

Growth Drivers: Osteoarthritis Prevalence and Non-Surgical Treatment Demand

The increasing occurrence of osteoarthritis is considered to be one of the key drivers fueling the Viscosupplementation Market due to the aging population, inactive lifestyle, and obesity, which result in progressive degeneration of articular cartilage in millions of people globally. The trend is additionally fueled by patients’ increasing tendency to choose minimally invasive treatment options, which will help them postpone or skip joint replacements surgery.

Increasing developments in the field of manufacturing high-quality hyaluronic acid is seen as another important source of demand for the market as this factor allows increasing the quality and cost-effectiveness of manufacturing processes. Increasing adoption of clinical guidelines recommending single-shot injections in contrast to multiple doses is another factor promoting the market.

Restraints: Alternative Therapies and Reimbursement Limitations

The presence of alternative knee osteoarthritis therapies, including corticosteroid injections and emerging regenerative medicine approaches, represents a significant restraint on the Viscosupplementation Market, as some clinical studies have found alternative treatments superior in specific short-term pain reduction measures. This dynamic is compounded by reimbursement limitations and lack of uniform clinical guidelines across different healthcare systems, which continue to create inconsistent treatment access for patients.

High treatment costs relative to alternative pain management options restrict broader adoption among cost-sensitive patient populations, particularly in markets with limited insurance coverage for viscosupplementation procedures. Continued potential side effects, including temporary joint pain or swelling, add further complexity to patient and provider treatment decision-making.

Opportunities: Regenerative Medicine Pipeline Expansion and Emerging Market Access

The development of next generation regenerative products based on hyaluronic acid holds immense promise for the Viscosupplementation Market due to the ongoing innovation efforts aimed at cartilage regeneration as well as next generation pain management techniques for osteoarthritis which still have unmet needs in the market.

The increase in initiatives to make viscosupplementation available to patients in emerging markets, through cooperation with academic institutions and charities aimed at subsidizing osteoarthritis campaigns, represents an opportunity that manufacturers will be able to take advantage of in the future as the healthcare system in those regions develops. Manufacturers that already have an existing distribution network in emerging markets stand to capture an outsized portion of this demand.

Recent Developments:

• 2026: Fidia Pharma launched HYMOVIS ONE in the U.S., a single-injection, non-crosslinked hyaluronan hydrogel for knee osteoarthritis, following FDA premarket approval in April 2025.

• 2024: Bioventus sold its Advanced Rehabilitation division to Accelmed Partners for approximately USD 45 million plus dependent earn-outs, reflecting continued portfolio optimization among leading viscosupplementation manufacturers.

Viscosupplementation Market Key Players are:

• Sanofi S.A.

• Bioventus Inc.

• Zimmer Biomet Holdings, Inc.

• Ferring Pharmaceuticals

• Anika Therapeutics, Inc.

• Seikagaku Corporation

• Fidia Farmaceutici S.p.A.

• Smith & Nephew plc

• CONTIPRO a.s.

• LG Chem Ltd.

• Bloomage Biotechnology Corporation Limited

• Viatris Inc.

• Chugai Pharmaceutical Co., Ltd.

• TRB Chemedica International SA

• Kolon TissueGene, Inc.

• OrthogenRx, Inc.

• Teva Pharmaceutical Industries Ltd.

• APTISSEN

• Avanos Medical, Inc.

• Johnson & Johnson Services, Inc.

Viscosupplementation Market Report Scope: